




R-PHARM

Innovative  
health  
technologies

# R-PHARM ANTIMICROBIAL PROJECTS

Second UK-Russia roundtable discussion – Antimicrobial resistance (AMR): action plans implementation  
20-21.03.2017



















### *Key facts*

- Established in 2001, fully private.
- The leading Russian vertically integrated pharmaceutical company.
- Products from a broad number of therapeutic areas in specialty/hospital care.
- Preferred partner for global Pharma leaders.
- 3,500+ employees at 50+ branches.
- Presence in 9 countries.
- RUR 77,6+ B revenue in 2016.

# Currently, R-Pharm has over 70 in-licensed / co-promoted products with global pharma players

Therapeutic area	Partner Company	Products
<p><b>Oncology</b></p>	  	<ul style="list-style-type: none"> <li>• Avastin</li> <li>• Herceptin</li> <li>• Tarceva</li> <li>• Xeloda</li> <li>• Beyodaym</li> <li>• Kadcyła</li> <li>• Keytruda</li> <li>• Sprycel</li> </ul>
<p><b>HIV / AIDS / Hepatitis treatment</b></p>	   	<ul style="list-style-type: none"> <li>• Kaletra</li> <li>• Viekira Pak</li> <li>• Isentress</li> <li>• Reyataz</li> <li>• Baraclude</li> <li>• Daklinza</li> <li>• Sebivo</li> </ul>
<p><b>Anti-infections</b></p>	  	<ul style="list-style-type: none"> <li>• Tienam</li> <li>• Invanz</li> <li>• Cubicin</li> <li>• Spectracef</li> <li>• Vibativ</li> </ul>
<p><b>Anti- inflammatory</b></p>		<ul style="list-style-type: none"> <li>• Humira</li> </ul>
<p><b>Other</b></p>	   	<ul style="list-style-type: none"> <li>• Prograf</li> <li>• De-Nol</li> <li>• Duodopa</li> <li>• Humalog</li> <li>• Aubagio</li> </ul>

# R-Pharm uniquely positioned to support international players in Russia and beyond

## R-Pharm value proposition

- Unmatched commercialization power in Russia and CIS.
- Compliant partner with strong reputation.
- Very experienced commercial groups in Russia, CIS & EEU, Turkey/MENA and US driving partnering deals.
- Highly professional Development & Regulatory, with fast track opportunities.
- State of the art manufacturing (Solid forms, Sterile F&F, Biologics, API).

## Current partners

<b>Development</b>	         
<b>Manufacturing</b>	               
<b>Promotion</b>	            

## Announced antimicrobial R&D partnerships (1)



### Telavancin and TD-1792 (Theravance)

- Innovative antibiotics for the treatment of resistant Gram-positive infections.
- Both antibiotics are indicated for the treatment severe infections (such as skin and soft tissue infections, nosocomial pneumonia, diabetic foot etc.), including those associated with methicillin-resistant *Staphylococcus aureus* (MRSA).
- Telavancin (Vibativ) has received MA in Russia, June 2015 , ongoing successful commercialization
- TD-1792 phase III study SSTI has been completed in 2016

## Announced antimicrobial R&D partnerships (2)



### Nemonoxacin (TaiGen)

- Nemonoxacin is a novel non-fluorinated quinolone active against drug-resistant bacteria. Phase II and III trials completed in Taiwan, China and the US. QIDP and Fast Track designations by US FDA for CAP and ABSSSI.
- Nemonoxacin has shown higher efficacy and improved safety and tolerability profile.
- R-PHARM has exclusive rights to develop and commercialize Nemonoxacin in Russia, CIS & EEU and Turkey.

## Announced antimicrobial R&D partnerships (3)



### SCY-078 (Scynexis)

- SCY-078 is the first-in-class oral inhibitor of glucan synthase developed for the treatment of systemic fungal infections (candidiasis and aspergillosis).
- SCY-078 has a good safety and tolerability profile.
- R-PHARM has exclusive rights to develop and commercialize the drug SCY-078 in Russia, CIS & EEU, Turkey, MENA, Balkans.


# Investment in our footprint outside Russia



2014 acquisition of a manufacturing asset in Germany



2013 launch of research collaboration in Japan



2014 R-Pharm US LLC est. in the US



2011 R&D and BD company est. in the US



2014 API and F&F site in Turkey being designed




2013 majority owned affiliate set up in Turkey



2014 Commercial entity established in UAE



2010 R&D partnership in India established

 R-Pharm with local activities